Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice.
OBJECTIVE
The aim of this study was to determine the dependency on peroxisome proliferator-activated receptor-gamma (PPAR-gamma) of insulin sensitisation and glucose homeostasis by thiazolidinediones using a global Ppar-gamma (also known as Pparg)-knockout mouse model.


METHODS
Global Mox2-Cre-Ppar-gamma-knockout (MORE-PGKO) mice were treated with rosiglitazone and analysed for insulin sensitivity and glucose metabolism. Metabolic and hormonal variables were determined. Adipose and other tissues were measured and analysed for gene expression.


RESULTS
Rosiglitazone induced regrowth of fat in female but not male MORE-PGKO mice, and only in specific depots. Insulin sensitivity increased but, surprisingly, was not associated with the typical changes in adipokines, plasma NEFA or tissue triacylglycerol. However, increases in alternatively activated macrophage markers, which have been previously associated with metabolic improvement, were observed in the regrown fat. Rosiglitazone improved glucose homeostasis but not insulin sensitivity in male MORE-PGKO mice, with further increase of insulin associated with an apparent expansion of pancreatic islets.


CONCLUSIONS
Stimulating fat growth by rosiglitazone is sufficient to improve insulin sensitivity in female mice with 95% PPAR-gamma deficiency. This increase in insulin sensitivity is not likely to be due to changes typically seen in adipokines or lipids but may involve changes in macrophage polarisation that occur independent of PPAR-gamma. In contrast, rosiglitazone improves glucose homeostasis in male mice with similar PPAR-gamma deficiency by increasing insulin production independent of changes in adiposity. Further, the insulin-sensitising effect of rosiglitazone is dependent on PPAR-gamma in this male lipodystrophic model.
Duan
S Z
SZ
Department of Internal Medicine, Nephrology Division, University of Michigan Medical School, Ann Arbor, MI, USA.
Usher
M G
MG
Foley
E L
EL
Milstone
D S
DS
Brosius
F C
FC
Mortensen
R M
RM
D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D015139:Blotting, Southern; D015153:Blotting, Western; D004797:Enzyme-Linked Immunosorbent Assay; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D005260:Female; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007333:Insulin Resistance / Q000235:genetics / Q000502:physiology; D050356:Lipid Metabolism / Q000187:drug effects; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D047495:PPAR gamma / Q000235:genetics / Q000502:physiology*; D000077154:Rosiglitazone; D012727:Sex Characteristics; D045162:Thiazolidinediones / Q000494:pharmacology*
D005230:Fatty Acids, Nonesterified; D007004:Hypoglycemic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone
Am J Physiol Endocrinol Metab. 2004 Feb;286(2):E252-60
14570702
J Clin Invest. 2000 Feb;105(3):271-8
10675352
Trends Pharmacol Sci. 2005 May;26(5):244-51
15860371
J Clin Invest. 2008 Sep;118(9):2992-3002
18769626
Diabetes. 2001 Aug;50(8):1863-71
11473050
Diabetologia. 1984 Aug;27(2):225-34
6386585
Mol Cell. 1999 Oct;4(4):585-95
10549290
Genes Dev. 1994 May 15;8(10):1224-34
7926726
Front Biosci. 2008 Jan 01;13:453-61
17981560
J Clin Invest. 2007 Mar;117(3):812-22
17304352
J Clin Invest. 2000 Nov;106(10):1221-8
11086023
Breast Cancer Res Treat. 2008 Dec;112(3):437-51
18204896
Circ Res. 2005 Aug 19;97(4):372-9
16051889
Cell Metab. 2008 Jun;7(6):496-507
18522831
Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L970-8
19346435
J Biol Chem. 1995 Jun 2;270(22):12953-6
7768881
Cell Metab. 2007 Aug;6(2):137-43
17681149
J Clin Invest. 2007 Jan;117(1):175-84
17200717
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15712-7
14660788
J Clin Invest. 1997 Dec 15;100(12):3149-53
9399962
J Clin Invest. 1997 Dec 1;100(11):2900-8
9389757
Nat Rev Immunol. 2008 Dec;8(12):958-69
19029990
Endocrinology. 2004 Jan;145(1):401-6
14500573
Nat Rev Immunol. 2003 Jan;3(1):23-35
12511873
Nat Med. 2003 Dec;9(12):1491-7
14625542
N Engl J Med. 2003 Dec 25;349(26):2560-2
14695419
Mol Cell Biol. 2003 Oct;23(20):7222-9
14517292
J Clin Endocrinol Metab. 2001 Oct;86(10):5045-51
11600583
Cell Metab. 2008 Jun;7(6):485-95
18522830
Am J Physiol Endocrinol Metab. 2005 Mar;288(3):E510-8
15522998
J Biol Chem. 2003 Sep 5;278(36):34268-76
12805374
Diabetes. 2005 Dec;54(12):3358-70
16306350
Nature. 1998 Jan 1;391(6662):79-82
9422508
Physiol Rev. 2004 Jan;84(1):277-359
14715917
PPAR Res. 2008;2008:169414
18615187
J Clin Invest. 1998 Mar 15;101(6):1354-61
9502777
Annu Rev Biochem. 2008;77:289-312
18518822
J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91
12050251
Diabetes. 2003 Jun;52(6):1311-8
12765938
J Clin Invest. 2007 Jun;117(6):1658-69
17525798
Metabolism. 1991 Nov;40(11):1213-8
1943750
J Biol Chem. 2001 Nov 2;276(44):41245-54
11533050
Mol Cell. 1999 Oct;4(4):611-7
10549292
Nature. 2007 Jun 28;447(7148):1116-20
17515919
Diabetes. 2009 Apr;58(4):803-12
19136652
Biochem Biophys Res Commun. 2003 Jan 10;300(2):429-36
12504102
J Biol Chem. 2008 Aug 15;283(33):22620-7
18541527
Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):7921-6
9223288
J Biol Chem. 2000 Mar 24;275(12):8456-60
10722680
J Clin Invest. 2003 Mar;111(5):737-47
12618528